[

serum institute

]

Latest from serum institute

Monkeypox: As India sees rise in cases, what Adar Poonawalla said about vaccine

India has so far reported eight cases of monkeypox, of which five have been from Kerala and three from Delhi. Of the five patients in Kerala, one succumbed to the disease on July 30, making it India's first monkeypox fatality.

Adar Poonawalla, chief executive officer of Serum Institute of India Ltd. (Bloomberg)
Adar Poonawalla, chief executive officer of Serum Institute of India Ltd. (Bloomberg)
Published on Aug 02, 2022 05:41 PM IST
Written by Sharangee Dutta | Edited by Aniruddha Dhar, New Delhi

SII to manufacture India’s 1st vaccine against cervical cancer after DGCI nod

Cervical cancer is the second most frequent cancer among women in India between the ages of 15 and 44.

For the first time there will be an Indian HPV vaccine to treat cervical cancer in women that is both affordable and accessible, SII CEO Adar Poonawalla tweeted. (Reuters file photo)
For the first time there will be an Indian HPV vaccine to treat cervical cancer in women that is both affordable and accessible, SII CEO Adar Poonawalla tweeted. (Reuters file photo)
Published on Jul 12, 2022 10:48 PM IST
Written by Harshit Sabarwal | Edited by Sohini Goswami, New Delhi

Serum institute seeks government nod to export Covovax to the US

SII manufactures Covovax under a license from the vaccine’s developer, US-based Novavax. The export version of the vaccine is called Nuvaxovid and has been dispatched to New Zealand, Netherlands, Australia and Indonesia, where a total of at least 100 million doses have been sent.

SII chief executive officer Adar Poonawalla. (REUTERS)
SII chief executive officer Adar Poonawalla. (REUTERS)
Published on Jul 01, 2022 03:16 AM IST
By, New Delhi

DGCI approves Serum Institute of India's Covovax for children aged 7 to 12 years

The DCGI's nod came after the subject expert committee on COVID-19 of the CSDCO last week recommended granting emergency use authorisation to Covovax for the age group of 7 to 11 years.

Covovax approved for restricted emergency use in children aged 7 to 11 years. (PIC for representation)
Covovax approved for restricted emergency use in children aged 7 to 11 years. (PIC for representation)
Published on Jun 28, 2022 10:26 PM IST
PTI | , New Delhi

Serum Institute seeks emergency use nod for its rBCG tuberculosis vaccine

India's TB immunisation programme currently offers BCG vaccination at birth or as early as possible till one year of age.

World Tuberculosis Day: Expert offers insights on causes and prevention of TB(Unsplash)
World Tuberculosis Day: Expert offers insights on causes and prevention of TB(Unsplash)
Published on Mar 27, 2022 10:28 PM IST
PTI | , New Delhi
Story Saved
×
Saved Articles
Following
My Reads
My Offers
Sign out
New Delhi 0C
Saturday, October 01, 2022
Start 15 Days Free Trial Subscribe Now
Register Free and get Exciting Deals